ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

LeMaistre To Retire As M.D. Anderson President In 1996

August 18, 1995

Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden

July 26, 2013

Manipulating The Therapeutic Index Clinical Trials Goal: Hellman

June 13, 1980

FDA, CMS Take Second Look at Drugs Given “Accelerated” Approval for Cancer

March 21, 2003

NCI Cooperative Group Clinical Trials Approved

August 27, 2010

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

October 31, 2003